Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford and its Clinical BioManufacturing Facility have approached MHRA in order to receive feedback, guidance and support in the development and manufacture of a candidate vaccine for treatment of malaria that has seen them explore an innovative approach to viral vectors using a chimpanzee virus.